At the same rate, another third (7/21) of the CUP cases in this cohort were refined to CCA after secondary review, all of which, again, had clinically actionable biomarkers, including IDH1 mutations or FGFR2 fusion. The gene discussed is IDH1; the disease is cholangiocarcinoma.